Valuation Neurocrine Biosciences, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 22:03:15 17/04/2026 HKT			5-day change	1st Jan Change
130.49 ^USD	+1.62%		-0.11%	-9.23%

04-14	Neurocrine Biosciences Presents Real-World Claims Analysis Demonstrating Greater Treatment Persistence With INGREZZA Capsules Compared To AUSTEDO XR	CI
04-13	Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	8,080	11,482	12,946	13,820	14,141	12,888	-	-
Change	-	42.11%	12.74%	6.76%	2.32%	-8.86%	-	-
Enterprise Value (EV) ¹	7,704	10,363	11,397	12,005	11,598	9,507	9,957	12,888
Change	-	34.52%	9.97%	5.33%	-3.39%	-18.02%	4.73%	29.44%
P/E ratio	92.6x	76.6x	53.3x	41.5x	30.4x	21.1x	17.1x	12.6x
PBR	5.86x	6.75x	5.83x	5.24x	4.36x	3.09x	2.57x	2.12x
PEG	-	1.1x	0.9x	1.3x	0.7x	0.7x	0.7x	0.4x
Capitalization / Revenue	7.13x	7.71x	6.86x	5.87x	4.94x	3.76x	3.44x	3.12x
EV / Revenue	6.8x	6.96x	6.04x	5.1x	4.05x	2.77x	2.66x	3.12x
EV / EBITDA	58.9x	39.2x	42.4x	20.1x	17.9x	12.7x	11.5x	11.2x
EV / EBIT	75.2x	41.6x	45.4x	21x	18.7x	13.2x	10.9x	10.3x
EV / FCF	33x	32.1x	31.5x	21.5x	15.5x	12.4x	10.2x	11.6x
FCF Yield	3.03%	3.12%	3.17%	4.64%	6.46%	8.06%	9.79%	8.61%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	0.92	1.56	2.47	3.29	4.67	6.091	7.523	10.18
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	1,134	1,489	1,887	2,355	2,860	3,429	3,746	4,128
EBITDA ¹	130.7	264.1	268.7	597.6	649.2	747.3	864.4	1,150
EBIT ¹	102.5	249	250.9	570.5	619.1	718.6	909.4	1,256
Net income ¹	89.6	154.5	249.7	341.3	478.6	639.1	792	1,080
Net Debt ¹	-376.2	-1,119	-1,549	-1,816	-2,543	-3,380	-2,931	-
Reference price ²	85.17	119.44	131.76	136.50	141.83	128.41	128.41	128.41
Nbr of stocks (in thousands)	94,867	96,134	98,252	101,247	99,706	100,363	-	-
Announcement Date	11/2/22	6/2/23	7/2/24	6/2/25	11/2/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NEUROCRINE BIOSCIENCES, INC.	21.08x	2.77x	12.72x	-.--%	12.89B
ELI LILLY AND COMPANY	26.9x	10.08x	20.2x	0.75%	809B
JOHNSON & JOHNSON	25.14x	5.78x	15.69x	2.27%	565B
ABBVIE INC.	23.52x	6.29x	12.77x	3.31%	370B
ASTRAZENECA PLC	25.36x	5.24x	14.79x	1.65%	312B
MERCK & CO., INC.	27.32x	4.77x	14.81x	2.93%	285B
NOVARTIS AG	20.77x	5.58x	13.5x	2.95%	286B
AMGEN INC.	23.43x	6.05x	10.71x	2.88%	189B
NOVO NORDISK A/S	12.28x	4.38x	9.16x	4.19%	180B
Average	22.87x	5.66x	13.82x	2.33%	334.17B
Weighted average by Cap.	24.34x	6.75x	15.44x	2.2%